Fifty 1 Labs, Inc. (OTC: FITY) and UAV Corp (OTC: UMAV) have announced a bold, AI-driven strategy aimed at reaching a $50 million valuation and securing an uplisting to the NASDAQ Capital Market. This strategic move underscores the companies' commitment to leveraging artificial intelligence in the drug repurposing and functional medicine sectors, with a goal to disrupt the $320.6 billion functional medicine market.
The strategy includes a $1 million R&D initiative through Fifty1 AI Labs LLC, a wholly owned subsidiary of FITY, to discover repurposed treatments by May 2026. Additionally, the company plans to launch a digital platform by July 31, 2025, and pursue biotech acquisitions in the $5–10 million range. A Q3 2025 shareholder event is also on the agenda, signaling the company's proactive approach to engaging with its investors.
Backed by a $350,000 insider investment and leadership salary deferrals, FITY's leadership team, including Nobel laureate Dr. James Orbinski and NFL veteran Brandon Spikes, is poised to drive the company towards its ambitious goals. The focus on personalized AI-powered healthcare solutions represents a significant shift in how healthcare and wellness could be approached in the future.
For more information on Fifty 1 Labs, Inc. and its initiatives, visit https://fifty1labs.com/.
